KDR and pulmonary hypertension: Therefore, although PD1 and PD-L1 inhibitors have not been associated with the development of pulmonary hypertension [27], this ensuing pro-inflammatory state may act synergistically with VEGFR inhibition to disrupt angiogenesis and promote abnormal vessel formation [18].